AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27633636 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed methods including semistructured interviews and quantitative process data analysis.
Number of subjects: 0
Study 27633636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost data analysis from patients and families perspective.
Number of subjects: 0
Study 25056464 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone (group A, n=51)
Number of subjects: 133
Study 25056464 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized vaginal progesterone (group B, n=50)
Number of subjects: 133
Study 25056464 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women without history of recurrent miscarriage (group C, n=32)
Number of subjects: 133
Study 22772417 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation management (treatment group)
Number of subjects: 56
Study 22772417 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rehabilitation management)
Number of subjects: 56
Study 20117625 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement and synovectomy
Number of subjects: 23
Study 20117625 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative therapy (control)
Number of subjects: 23
Study 17955571 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-voxel 1H MRS (SV-MRS)
Number of subjects: 10
Study 17955571 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectroscopic imaging (MRSI)
Number of subjects: 10
Study 17955571 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSI
Number of subjects: 10
Study 17955571 — intervention group
Group type: COMPARATOR
Intervention: MRSI vs SV-MRS
Number of subjects: 10
Study 16836502 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergized pyrethrins foam (PF) for 3 days
Number of subjects: 240
Study 16836502 — intervention group
Group type: COMPARATOR
Intervention: Benzyl benzoate (BB) lotion for 5 days
Number of subjects: 240
Study 16836502 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerability score for PF
Number of subjects: 240
Study 16836502 — intervention group
Group type: COMPARATOR
Intervention: Tolerability score for BB
Number of subjects: 240
Study 11261827 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 60 mgs/day
Number of subjects: 217
Study 11261827 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 40 mgs/day
Number of subjects: 217
Study 11261827 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR)
Number of subjects: 217
Study 11261827 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 217
Study 11261827 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) and Tamoxifen (TAM)
Number of subjects: 217
Study 9557098 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllin 0.5% in ethanol (PE)
Number of subjects: 35
Study 9557098 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllin 0.25% in ethanol (PE)
Number of subjects: 35
Study 9557098 — intervention group
Group type: COMPARATOR
Intervention: Podophyllin 25% in tincture benzoin (PB)
Number of subjects: 35
Study 8002875 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention
Number of subjects: 17460
Study 8002875 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention with effective cholesterol lowering
Number of subjects: 17460
Study 8002875 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention in angiographic trials
Number of subjects: 17460
Study 8002875 — intervention group
Group type: COMPARATOR
Intervention: Fish oil after coronary angioplasty
Number of subjects: 17460
Study 2702160 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy by dental school assistants (experimental group)
Number of subjects: 50
Study 2702160 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods by students (control group)
Number of subjects: 50
Study 4311188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylamphetamine
Number of subjects: 0
Study 4311188 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamphetamine
Number of subjects: 0
Study 30223381 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound treatment
Number of subjects: 54
Study 30223381 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound treatment
Number of subjects: 54
Study 30223381 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound treatment
Number of subjects: 54
Study 27385192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 0
Study 27385192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24982002 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and stability-focused rehabilitation
Number of subjects: 50
Study 24982002 — intervention group
Group type: COMPARATOR
Intervention: Regular physiotherapy
Number of subjects: 50
Study 22269538 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-evaluative performance feedback
Number of subjects: 0
Study 22269538 — intervention group
Group type: COMPARATOR
Intervention: No feedback (Control)
Number of subjects: 0
Study 19857039 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (radiotherapy or radiochemotherapy)
Number of subjects: 0
Study 19857039 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study 18598323 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG roller pump CPB
Number of subjects: 30
Study 18598323 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG centrifugal vortex pump CPB
Number of subjects: 30
Study 18598323 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart valve surgery roller pump CPB
Number of subjects: 30
Study 18598323 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study 15818076 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 1703
Study 15818076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1703
Study 15818076 — intervention group
Group type: COMPARATOR
Intervention: Nonselective nonsteroidal anti‐inflammatory drug
Number of subjects: 1703
Study 11910256 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (200 mg, bid)
Number of subjects: 36
Study 11910256 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (3 mg, bid)
Number of subjects: 36
Study 11910256 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (7.5 mg, bid)
Number of subjects: 36
Study 11910256 — intervention group
Group type: EXPERIMENTAL
Intervention: All three coadministered therapies
Number of subjects: 36
Study 11910256 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy transitioning to coadministration
Number of subjects: 36
Study 11122797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0
Study 11122797 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracyclines, platinum compounds, and paclitaxel
Number of subjects: 0
Study 11122797 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0
Study 11122797 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical determination of tumor receptor status
Number of subjects: 0
Study 11122797 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HER2/neu monoclonal antibody
Number of subjects: 0
Study 8669350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-at-Home (HAH) rehabilitation team
Number of subjects: 60
Study 8669350 — intervention group
Group type: COMPARATOR
Intervention: Conventional discharge (CD) preparation
Number of subjects: 60
Study 2354058 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze test measuring path length traced in 1 minute
Number of subjects: 50
Study 2354058 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze test
Number of subjects: 50
Study 2354058 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue sedation scale
Number of subjects: 50
Study 2354058 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative maze scores
Number of subjects: 50
Study 683909 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra potassium supplements
Number of subjects: 49
Study 683909 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 49
Study 683909 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 49
Study 30786793 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% sucrose solution
Number of subjects: 56
Study 30786793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 29056520 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS 0.5 ng/kg
Number of subjects: 24
Study 29056520 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS 1 ng/kg
Number of subjects: 24
Study 29056520 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS 2 ng/kg
Number of subjects: 24
Study 29056520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27001804 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of PXVX0200 (approximately 5 × 10(8) CFU)
Number of subjects: 197
Study 27001804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 24647737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 36
Study 24647737 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.i.d.)
Number of subjects: 36
Study 24647737 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 36
Study 22699130 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency TENS
Number of subjects: 20
Study 22699130 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 20
Study 20829597 — intervention group
Group type: EXPERIMENTAL
Intervention: Local thermal stimulation of the paraumbilical region for 20 min at a temperature of 40 °C (Group A)
Number of subjects: 28
Study 20829597 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine Daikenchuto (TJ‐100; 5.0 g) with distilled water (Group B)
Number of subjects: 28
Study 20829597 — intervention group
Group type: COMPARATOR
Intervention: Distilled water alone (Group C)
Number of subjects: 28
Study 17079360 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldenseal (3210 mg daily for 14 days)
Number of subjects: 20
Study 17079360 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava kava (1227 mg daily for 14 days)
Number of subjects: 20
Study 17079360 — intervention group
Group type: COMPARATOR
Intervention: Rifampin (600 mg daily for 7 days)
Number of subjects: 20
Study 17079360 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (1000 mg daily for 7 days)
Number of subjects: 20
Study 16244024 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion via 2 epidural catheters for postoperative analgesia (group E)
Number of subjects: 30
Study 16244024 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative general anesthesia and postoperative IV morphine analgesia (group G)
Number of subjects: 30
Study 12107602 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg daily
Number of subjects: 110
Study 12107602 — intervention group
Group type: COMPARATOR
Intervention: atenolol 50 mg daily
Number of subjects: 110
Study 10338217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (GLN) 10 g three times daily
Number of subjects: 66
Study 10338217 — intervention group
Group type: COMPARATOR
Intervention: Glycine-control (GLY) 10 g three times daily
Number of subjects: 66
Study 10338217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (GLN)
Number of subjects: 66
Study 10338217 — intervention group
Group type: COMPARATOR
Intervention: Glycine-control (GLY)
Number of subjects: 66
Study 10338217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and parenteral glutamine (GLN)
Number of subjects: 66
Study 8747034 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day for 6 months
Number of subjects: 30
Study 8747034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1903079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocryptine (DEK) at mean daily doses of approximately 40 mg (ranging from 15 to 60 mg)
Number of subjects: 20
Study 1903079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7381028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (200 mg orally three times a day)
Number of subjects: 0
Study 7381028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 0
Study 7381028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31725021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 60
Study 31725021 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 60
Study 30426214 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month intervention including education and support to reduce intakes of fat and total calories
Number of subjects: 578
Study 30426214 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 578
Study 28671933 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-km treadmill walking test
Number of subjects: 50
Study 25640616 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental endoscopy‐assisted training program
Number of subjects: 6
Study 25640616 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration training
Number of subjects: 6
Study 24556530 — intervention group
Group type: COMPARATOR
Intervention: TBP condition in POD (n=41)
Number of subjects: 90
Study 24556530 — intervention group
Group type: EXPERIMENTAL
Intervention: TBP condition in mPOD (n=49)
Number of subjects: 90
Study 24556530 — intervention group
Group type: EXPERIMENTAL
Intervention: TBP+mobile group in mPOD (n=47)
Number of subjects: 90
Study 24556530 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile users for podcasts
Number of subjects: 90
Study 24556530 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitter mobile app users
Number of subjects: 90
Study 21785889 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminar
Number of subjects: 648
Study 21785889 — intervention group
Group type: EXPERIMENTAL
Intervention: CD
Number of subjects: 648
Study 21785889 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (untrained)
Number of subjects: 648
Study 19540659 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound (LIPUS) treatment
Number of subjects: 44
Study 19540659 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study 17440643 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (L) 50 mg plus Hydrochlorothiazide (HCTZ) 12.5 mg titrated to L 100 mg plus HCTZ 25 mg
Number of subjects: 0
Study 17440643 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (L) and Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 17440643 — intervention group
Group type: COMPARATOR
Intervention: Stepped-care (HCTZ 12.5 mg plus Atenolol 50 mg)
Number of subjects: 0
Study 15239726 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum mast cell tryptase measurement
Number of subjects: 64
Study 15239726 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial tryptase measurement
Number of subjects: 64
Study 15239726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tryptase and histamine measurements
Number of subjects: 64
Study 12185869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical suture with closed technique
Number of subjects: 100
Study 12185869 — intervention group
Group type: COMPARATOR
Intervention: Manual suture
Number of subjects: 100
Study 12185869 — intervention group
Group type: COMPARATOR
Intervention: Mechanical suture with open technique
Number of subjects: 100
Study 9627939 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against pertussis
Number of subjects: 16500
Study 9627939 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against measles
Number of subjects: 16500
Study 9627939 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against rubella
Number of subjects: 16500
Study 9627939 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against mumps
Number of subjects: 16500
Study 9627939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubini strain vaccination
Number of subjects: 16500
Study 8250765 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (900 micrograms/d administered intranasally)
Number of subjects: 19
Study 8250765 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (400 mg/d p.o.)
Number of subjects: 19
Study 8250765 — intervention group
Group type: COMPARATOR
Intervention: Buserelin
Number of subjects: 19
Study 8250765 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 19
Study 3533825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (2.5 mg) + 573 mg potassium chloride 3 times a day
Number of subjects: 22
Study 3533825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31788880 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-curcumin (80 mg daily for 8 weeks)
Number of subjects: 80
Study 31788880 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 30588501 — intervention group
Group type: EXPERIMENTAL
Intervention: DCGAN-created brain MR images
Number of subjects: 63
Study 30588501 — intervention group
Group type: COMPARATOR
Intervention: Real brain MR images
Number of subjects: 63
Study 27694598 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed splinting for type I fractures
Number of subjects: 81
Study 27694598 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment for type III fractures
Number of subjects: 81
Study 27694598 — intervention group
Group type: COMPARATOR
Intervention: Normal age- and gender-matched individuals (control group)
Number of subjects: 81
Study 27694598 — intervention group
Group type: EXPERIMENTAL
Intervention: Type III fractures
Number of subjects: 81
Study 27694598 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 81
Study 24567202 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes report card with letter grades (A to F)
Number of subjects: 177
Study 24567202 — intervention group
Group type: EXPERIMENTAL
Intervention: Report card with face reflecting glycemic control
Number of subjects: 177
Study 24567202 — intervention group
Group type: COMPARATOR
Intervention: Standard report card with A1C value
Number of subjects: 177
Study 22189524 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin or first-generation cephalosporin (IV for 2-4 days, then oral)
Number of subjects: 199
Study 20965458 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day home discharge with bolus-only abciximab regimen
Number of subjects: 1005
Study 20965458 — intervention group
Group type: COMPARATOR
Intervention: Overnight hospitalization with 12-hour abciximab infusion
Number of subjects: 1005
Study 17410124 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBT986
Number of subjects: 48
Study 17410124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15818530 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 15818530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11939978 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacologic intervention
Number of subjects: 0
Study 11939978 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment phase
Number of subjects: 0
Study 9440419 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric (CON) training of the left quadriceps femoris (QF) for nine weeks
Number of subjects: 9
Study 9440419 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) assessment of cross-sectional area and spin-spin relaxation time (T2) of each QF before and 3 days after the ECC exercise bout
Number of subjects: 9
Study 7545721 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 7545721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2205994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 160
Study 2205994 — intervention group
Group type: COMPARATOR
Intervention: Control group without cerclage
Number of subjects: 160
Study 7215419 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 11
Study 30789515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential application of 1,450-nm diode laser and 450-nm blue light
Number of subjects: 24
Study 30789515 — intervention group
Group type: COMPARATOR
Intervention: 450-nm blue light alone
Number of subjects: 24
Study 28301865 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 60
Study 28301865 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and static ultrasound
Number of subjects: 60
Study 28301865 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and diadynamic currents
Number of subjects: 60
Study 25794691 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma (PRP) during myringoplasty
Number of subjects: 64
Study 25794691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP) during myringoplasty
Number of subjects: 64
Study 23723343 — intervention group
Group type: EXPERIMENTAL
Intervention: Provent
Number of subjects: 67
Study 23723343 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Provent
Number of subjects: 67
Study 23723343 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 67
Study 20551220 — intervention group
Group type: COMPARATOR
Intervention: Varenicline (0.25, 0.5, 1.0, 2.0 mg)
Number of subjects: 20
Study 20551220 — intervention group
Group type: COMPARATOR
Intervention: Varenicline (0.5 or 1.0 mg) twice daily
Number of subjects: 20
Study 20551220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19214045 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual stigma reduction program
Number of subjects: 86
Study 19214045 — intervention group
Group type: EXPERIMENTAL
Intervention: Control stigma reduction program
Number of subjects: 86
Study 19214045 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical stigma reduction program
Number of subjects: 86